Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.
Cardiometabolic Health Group, Precision Nutrition and Cardiometabolic Health Program, IMDEA Food, CEI UAM + CSIC, Madrid, Spain.
Am J Clin Nutr. 2022 Dec 19;116(6):1565-1579. doi: 10.1093/ajcn/nqac255.
Choline and betaine intakes have been related to cardiovascular health.
We aimed to explore the relation between 1-y changes in dietary intake of choline or betaine and 1-y changes in cardiometabolic and renal function traits within the frame of the PREDIMED (PREvención con DIeta MEDiterránea)-Plus trial.
We used baseline and 1-y follow-up data from 5613 participants (48.2% female and 51.8% male; mean ± SD age: 65.01 ± 4.91 y) to assess cardiometabolic traits, and 3367 participants to assess renal function, of the Spanish PREDIMED-Plus trial. Participants met ≥3 criteria of metabolic syndrome and had overweight or obesity [BMI (in kg/m2) ≥27 and ≤40]. These criteria were similar to those of the PREDIMED parent study. Dietary intakes of choline and betaine were estimated from the FFQ.
The greatest 1-y increase in dietary choline or betaine intake (quartile 4) was associated with improved serum glucose concentrations (-3.39 and -2.72 mg/dL for choline and betaine, respectively) and HbA1c levels (-0.10% for quartile 4 of either choline or betaine intake increase). Other significant changes associated with the greatest increase in choline or betaine intake were reduced body weight (-2.93 and -2.78 kg, respectively), BMI (-1.05 and -0.99, respectively), waist circumference (-3.37 and -3.26 cm, respectively), total cholesterol (-4.74 and -4.52 mg/dL, respectively), and LDL cholesterol (-4.30 and -4.16 mg/dL, respectively). Urine creatinine was reduced in quartile 4 of 1-y increase in choline or betaine intake (-5.42 and -5.74 mg/dL, respectively).
Increases in dietary choline or betaine intakes were longitudinally related to improvements in cardiometabolic parameters. Markers of renal function were also slightly improved, and they require further investigation.This trial was registered at https://www.isrctn.com/ as ISRCTN89898870.
胆碱和甜菜碱的摄入量与心血管健康有关。
我们旨在探讨在 PREvención con DIeta MEDiterránea-PLUS(PREDIMED)试验框架内,饮食中胆碱或甜菜碱摄入量在 1 年内的变化与心血管代谢和肾功能特征在 1 年内的变化之间的关系。
我们使用来自西班牙 PREDIMED-Plus 试验的 5613 名参与者(48.2%女性和 51.8%男性;平均年龄±标准差:65.01±4.91 岁)的基线和 1 年随访数据来评估心血管代谢特征,使用 3367 名参与者来评估肾脏功能。这些参与者符合代谢综合征的≥3 项标准,且超重或肥胖[体重指数(BMI)(kg/m2)≥27 和≤40]。这些标准与 PREDIMED 主要研究相似。胆碱和甜菜碱的饮食摄入量是从 FFQ 中估计的。
胆碱或甜菜碱摄入量最大的 1 年增加(第 4 四分位数)与血清葡萄糖浓度的改善有关(胆碱和甜菜碱分别为-3.39 和-2.72mg/dL)和 HbA1c 水平(胆碱或甜菜碱摄入量增加的第 4 四分位数分别为-0.10%)。与胆碱或甜菜碱摄入量最大增加相关的其他显著变化是体重减轻(分别为-2.93 和-2.78kg)、BMI(分别为-1.05 和-0.99)、腰围(分别为-3.37 和-3.26cm)、总胆固醇(分别为-4.74 和-4.52mg/dL)和 LDL 胆固醇(分别为-4.30 和-4.16mg/dL)。胆碱或甜菜碱摄入量 1 年增加的第 4 四分位数时尿肌酐减少(分别为-5.42 和-5.74mg/dL)。
饮食中胆碱或甜菜碱摄入量的增加与心血管代谢参数的改善呈纵向相关。肾功能指标也略有改善,需要进一步研究。该试验在 https://www.isrctn.com/ 注册为 ISRCTN89898870。